278 related articles for article (PubMed ID: 28968166)
1. Risk of Cardiovascular Ischemic Events After Surgical Castration and Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer: A Nationwide Cohort Study.
Chen DY; See LC; Liu JR; Chuang CK; Pang ST; Hsieh IC; Wen MS; Chen TH; Lin YC; Liaw CC; Hsu CL; Chang JW; Kuo CF; Huang WK
J Clin Oncol; 2017 Nov; 35(32):3697-3705. PubMed ID: 28968166
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.
Sun M; Choueiri TK; Hamnvik OP; Preston MA; De Velasco G; Jiang W; Loeb S; Nguyen PL; Trinh QD
JAMA Oncol; 2016 Apr; 2(4):500-7. PubMed ID: 26720632
[TBL] [Abstract][Full Text] [Related]
3. Risk of cardiovascular thrombotic events after surgical castration versus gonadotropin-releasing hormone agonists in Chinese men with prostate cancer.
Teoh JY; Chan SY; Chiu PK; Poon DM; Cheung HY; Hou SS; Ng CF
Asian J Androl; 2015; 17(3):493-6. PubMed ID: 25578930
[TBL] [Abstract][Full Text] [Related]
4. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study.
Jespersen CG; Nørgaard M; Borre M
Eur Urol; 2014 Apr; 65(4):704-9. PubMed ID: 23433805
[TBL] [Abstract][Full Text] [Related]
5. Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study.
Chen DY; Su PJ; See LC; Liu JR; Chuang CK; Pang ST; Tseng CN; Chen SW; Hsieh IC; Chu PH; Lin YC; Hsu CL; Chang JW; Lin MS; Pang JS; Hsieh MJ; Huang WK
Prostate; 2021 Sep; 81(12):902-912. PubMed ID: 34196430
[TBL] [Abstract][Full Text] [Related]
6. The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study.
Gandaglia G; Sun M; Popa I; Schiffmann J; Abdollah F; Trinh QD; Saad F; Graefen M; Briganti A; Montorsi F; Karakiewicz PI
BJU Int; 2014 Dec; 114(6b):E82-E89. PubMed ID: 24612110
[TBL] [Abstract][Full Text] [Related]
7. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.
Keating NL; O'Malley AJ; Freedland SJ; Smith MR
J Natl Cancer Inst; 2010 Jan; 102(1):39-46. PubMed ID: 19996060
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan.
Shao YJ; Hong JH; Chen CK; Huang CY
Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):722-729. PubMed ID: 35662291
[TBL] [Abstract][Full Text] [Related]
9. Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data.
Scailteux LM; Vincendeau S; Balusson F; Leclercq C; Happe A; Le Nautout B; Polard E; Nowak E; Oger E
Eur J Cancer; 2017 May; 77():99-108. PubMed ID: 28390298
[TBL] [Abstract][Full Text] [Related]
10. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
Keating NL; O'Malley AJ; Smith MR
J Clin Oncol; 2006 Sep; 24(27):4448-56. PubMed ID: 16983113
[TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.
Wu CT; Yang YH; Chen PC; Chen MF; Chen WC
Osteoporos Int; 2015 Sep; 26(9):2281-90. PubMed ID: 25990353
[TBL] [Abstract][Full Text] [Related]
12. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.
Bosco C; Bosnyak Z; Malmberg A; Adolfsson J; Keating NL; Van Hemelrijck M
Eur Urol; 2015 Sep; 68(3):386-96. PubMed ID: 25484142
[TBL] [Abstract][Full Text] [Related]
13. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer.
Gandaglia G; Sun M; Hu JC; Novara G; Choueiri TK; Nguyen PL; Schiffmann J; Graefen M; Shariat SF; Abdollah F; Briganti A; Montorsi F; Trinh QD; Karakiewicz PI
Eur Urol; 2014 Dec; 66(6):1125-32. PubMed ID: 24495466
[TBL] [Abstract][Full Text] [Related]
14. Type of Androgen Deprivation Therapy and Risk of Dementia Among Patients With Prostate Cancer in Taiwan.
Huang WK; Liu CH; Pang ST; Liu JR; Chang JW; Liaw CC; Hsu CL; Lin YC; See LC
JAMA Netw Open; 2020 Aug; 3(8):e2015189. PubMed ID: 32865575
[TBL] [Abstract][Full Text] [Related]
15. Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy.
O'Farrell S; Sandström K; Garmo H; Stattin P; Holmberg L; Adolfsson J; Van Hemelrijck M
BJU Int; 2016 Sep; 118(3):391-8. PubMed ID: 26497726
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Surgical or Medical Castration-Related Cardiotoxicity in Patients with Prostate Cancer.
Kan WC; Hsieh KL; Chen YC; Ho CH; Hong CS; Chiang CY; Wu NC; Chen M; Shih JY; Chen ZC; Chang WT
J Urol; 2022 Apr; 207(4):841-850. PubMed ID: 34854752
[TBL] [Abstract][Full Text] [Related]
17. The Use of Gonadotropin-Releasing Hormone Agonist Does Not Affect the Development of Cardiovascular Disease in Prostate Cancer Patients: a Nationwide Population-Based Cohort Study.
Shim M; Bang WJ; Oh CY; Lee YS; Jeon SS; Ahn H; Ju YS; Cho JS
J Korean Med Sci; 2020 Feb; 35(4):e47. PubMed ID: 31997617
[TBL] [Abstract][Full Text] [Related]
18. Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events.
Schmid M; Sammon JD; Reznor G; Kapoor V; Speed JM; Abdollah FA; Sood A; Chun FK; Kibel AS; Menon M; Fisch M; Sun M; Trinh QD
BJU Int; 2016 Aug; 118(2):221-9. PubMed ID: 26074405
[TBL] [Abstract][Full Text] [Related]
19. [Cardiovascular risks of androgen deprivation therapy for prostate cancer].
Miller K
Urologe A; 2016 May; 55(5):627-31. PubMed ID: 27003571
[TBL] [Abstract][Full Text] [Related]
20. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer.
Lapi F; Azoulay L; Niazi MT; Yin H; Benayoun S; Suissa S
JAMA; 2013 Jul; 310(3):289-96. PubMed ID: 23860987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
